



May 19, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Investor Presentation

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the investor presentation on financial results of the Company for the quarter and financial year ended on March 31, 2026.

The presentation is also being uploaded on the website of the company i.e. www.mankindpharma.com.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a



INVESTOR PRESENTATION

Q4 & FY26

May, 2026

Index

01

Financial Performance

- Key Financials - Q4 FY26
- P & L Highlights - Q4 & FY26
- Key Financial Metrics - FY26

02

Business Updates - Q4 FY26

- Domestic Business
- Consumer Healthcare Business
- Export Business
- ESG Updates

03

Additional Information

- Mankind Pharma at a Glance (FY26)
- Key Milestones
- Expansion in Specialty and Super Specialty Segments
- Key Strengths
- Strategy Going Ahead
- Financials - Steady Growth Trajectory
- Key Performance Highlights
- Shareholding Pattern
- Annexures
- Q4 & FY26 Earnings Call Details



Financial Performance


Q4 FY26 - Key Financial Snapshot

Financials / Margins	Growth	Capital Efficiency
3,443 Revenue (INR Cr)	11.8% YoY Growth	12% / 41% ROCE / Adj. ROCE ¹
910 / 26.4% EBITDA (INR Cr) / Margin	32.7% YoY Growth	3,932 Net Debt (INR Cr)
933 / 27.1% Adj. EBITDA ² / Margin	31.1% YoY Growth	1.1x Net Debt / EBITDA



Mr. Rajeev Juneja
Vice Chairman & Managing Director

Segmental Revenue Break - Up



- Revenue increased ~12% YoY with adj. EBITDA margins² of 27.1%
- Overall domestic business (ex CH) grew by ~13% led by:
 - ✓ double digit growth in Mankind domestic business led by 14.7% in cardiac and 11.6% in anti-diabetes (120 bps YoY increase in chronic share to ~40%)
 - ✓ sequential growth recovery in key acute therapies like Gastro, VMN, etc.
 - ✓ strong double digit growth in BSVs domestic business
- OTC business grew by 20% led by strong growth in e-commerce; International business witnessed muted growth due to geo-political headwinds
- We are on track in strengthening scale and advancing specialization through four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio to deliver long-term sustainable growth.


Q4 & FY26 - P&L Highlights¹

INR Cr	Q4FY26	Q4FY25	YoY Growth	Q3FY26	QoQ Growth	FY26	FY25	YoY Growth
Revenue from Operations (A=B+C)	3,443	3,079	11.8%	3,567	-3.5%	14,278	12,207	17.0%
Domestic Business (B)	2,886	2,544	13.4%	3,046	-5.3%	12,217	10,675	14.4%
i. Domestic Business (ex CH)	2,673	2,366	12.9%	2,843	-6.0%	11,338	9,866	14.9%
ii. Consumer Healthcare (CH)	213	178	19.8%	203	5.0%	879	809	8.7%
Exports Business (C)	557	535	4.2%	521	7.0%	2,061	1,532	34.5%
Gross Profit	2,485	2,204	12.7%	2,589	-4.0%	10,226	8,718	17.3%
EBITDA	910	686	32.7%	816	11.5%	3,499	3,030	15.5%
Profit After Tax	559	429	30.4%	414	35.2%	1,938	2,007	-3.4%
Diluted EPS ² (INR)	13.4	10.3	30.3%	9.9	35.6%	46.3	49.1	-5.7%
Cash EPS ² (INR)	19.1	15.9	20.5%	15.6	22.6%	68.1	64.4	5.6%
Gross Margins %	72.2%	71.6%	60 bps	72.6%	40 bps	71.6%	71.4%	20 bps
EBITDA Margins %	26.4%	22.3%	410 bps	22.9%	350 bps	24.5%	24.8%	30 bps
Adjusted EBITDA Margins %	27.1% ³	23.1% ⁴	400 bps	25.9% ³	120 bps	25.4% ³	25.9% ⁴	50 bps
PAT Margins %	16.2%	13.9%	230 bps	11.6%	460 bps	13.6%	16.4%	280 bps


1. Financials are for continuing operations only as reported in the respective periods || 2. Diluted EPS and Cash EPS not annualised || 3. Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results) || 4. Adjusted with one-time M&A related expenses and other non-recurring cost

Key Financial Metrics¹


Cash Flow from Operations (INR Cr)




CAPEX (INR Cr)




ROCE²



Net Cash / (Net Debt) (INR Cr)



Net Operating Working Capital Days




1. Above FY24 and FY25 P&L items are for continuing operations only || 2. On TTM Basis || 3. calculated on Adj. EBITDA basis | *Includes BSV from 23-Oct-2024 || Refer Annexure for Formulas



Business Updates

Domestic Business Performance

Strong Growth in Domestic Revenue^{1,2}



- ❖ Domestic revenue increased 13% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV specialty business
- ❖ Secondary sales³ growth of 8.7% vs 10.7% IPM⁴ in Q4FY26 – primarily due to
 - strong performance in chronic growth³ supported by 14.7% in Cardiac and 11.6% in Anti-Diabetes
 - muted growth in anti-infectives partially offset by sequential recovery in Gastro, VMN, Derma etc
- ❖ Strong growth in key focused brands:
 - outperformance in key acute brands like Cefakind-CV (1.3x), Nurokind-LC (1.1x), Pantakind (1.4x), Dydroboon (1.9x) etc in Q4FY26
 - c.16.5% growth³ in Telmikind family; 23.7% in Lipirose; 28.7% in Statpure in cardiac during Q4FY26
 - Glizid brand family crossed Rs 230 Cr in MAT Mar'26 (35%+ growth)³
- ❖ Healthy growth in BSVs key brands - Foligraf (52%), HMG (40%), Ossopan (72%), Lactare (46%) and Anti-D (100% market share) has grown 10%
- ❖ Consistently maintained #1 rank over last 9 years with prescription share of 15.1%³

Increased chronic share by 190 bps¹ in FY26





+




=



Consistent focus to increase chronic contribution




BSV's super specialty portfolio



- ❖ BSV's specialty complex portfolio, characterized by high entry barriers and limited competition, offers long-term growth potential due to its niche product offerings
- ❖ As per IQVIA, 84% of their domestic business is classified under the acute segment

Mankind Consolidated




- ❖ 1.1x outperformance to IPM in Cardiac and 2.1x outperformance to IPM in Anti-Diabetic² in FY26
- ❖ Consistent outperformance across portfolio supported by key strategic launches
 - 3x outperformance to IPM with 44% combined YoY growth in inhalers (Combihale & Symbicort) with >2% MS
 - 40% YoY growth in Nobeglar (Insulin Glargine) with >2% MS
 - #1 Rx brand Crenzlo in FY26

Q4 FY26 - Therapy wise Performance

High Ranks across Acute and Chronic Areas


Key Therapy Areas	Rank in CVM (Q4FY26)	MS% (Q4FY26)	FY 21-26 CAGR	
			Mankind ²	IPM
Chronic therapies	3	4.3%	14.3%	11.4%
Cardiovascular	4	5.6%	17.3%	11.1%
Anti Diabetic	4	4.4%	12.1%	8.2%
Acute therapies	2	5.0%	11.4%	9.6%
Anti-Infectives	5	5.9%	12.2%	10.3%
Gynaecology	1	11%	23.2%	10.1%
Gastro Int	7	4.2%	8.7%	10.5%
Respiratory	3	5.3%	13.9%	12.7%
Overall	2	4.7%	12.4%	10.3%

Q4FY26 - Sales Mix representing Diversified Therapy Presence




- Cardiovascular
- Anti-Infectives
- Gynaecology
- Gastro Intestinal
- Anti Diabetic
- Respiratory
- VMN
- Urology
- Dermatology
- Pain / Analgesics
- Neuro / CNS
- Others

Q4FY26 - Key Therapies Performance




FY26 Business Update¹


Mankind volume increased by 180 bps vs 130 bps IPM in FY26



1.1x outperformance to IPM chronic in FY26^{2,3}



FY26 - Key Therapies Performance




Consistently Built and Scaled Brands

Brand Families	FY 21	FY 26	CAGR (FY21-26)
> INR 500 Crore	0	3	14.4%
> INR 200 Crore	7	13	12.8%
> INR 100 Crore	15	22	12.3%
> INR 50 Crore	36	54	11.2%

Key Brands¹ >INR 500 Cr



Telmikind – Rs 783 Cr



Nurokind – Rs 667 Cr

Manforce – Rs 647 Cr

Key Brands¹ added in FY26 >INR 50 Cr



LACTARE




D3 MUST



STATPURE



MAHAFLOX

















OSSOPAN

As per IQVIA March-26 Including BSV || 1. Key brands refer to select Brand Families

Consistently Expanding Our Portfolio Towards Specialty Products




Therapy Area	Brand Launched (Year)	Indication	Reference Market Size (INR Cr) - FY26	Market 5 Year CAGR	Rationale
 CARDIAC	Neptaz # (FY22)	 Heart Failure	891 ¹	17%	<ul style="list-style-type: none"> • Neptaz - In-licensed from Novartis. Strong Revenue and Volume growth. Ranks in the top 5 in its market. • Crenzlo - In-licensed from Novartis, to foray into the latest generation lipid-lowering injectables through the patented drug 'Inclisran'.
	CRENZLO # (FY25)	 High LDL Cholesterol	747	60%	
 ANTI-DIABETIC	Nobeglar ® # (FY23)	 Type 1 and 2 Diabetes	4,911	5%	<ul style="list-style-type: none"> • In-licensed from Biocon, to foray in niche insulin category. • Launch of the year, with 1 lakh+ prescriptions within one year.
 RESPIRATORY	Combihale ® * (FY22)	 Chronic Obstructive Pulmonary Disease (COPD)	5,600	14%	<ul style="list-style-type: none"> • Combihale - acquired from DRL, to foray into the rapidly growing inhaler market. • Symbicort - Exclusive distribution agreement with AstraZeneca for India, marking our entry into the premium inhalation segment.
	Symbicort ® # (FY24)				
 DERMA	 Daffy * (FY22)	 Paediatric Skin and Hair care	3,289	14%	<ul style="list-style-type: none"> • Daffy, acquired from DRL, strong growth continues since its acquisition in 2022. • Foray into the infant skin and hair care category within the emollients section growing by 1.5X of IPM over the last 5 years.
 GASTRO INTESTINAL	VONATIME	 Gastroesophageal Reflux Disease (GERD)	10,851	8%	<ul style="list-style-type: none"> • Vonoprazan - In-licensed from Takeda, we aim to improve the quality of life for those suffering from acid-related illnesses. • GERD prevalence in the Indian population is ~8.2%, with a higher prevalence of around 11.1% in the urban population.
	VONALONG # (FY25)				
 CNS	Rivotril ® * (FY26)	 Epilepsy, Anxiety & Panic Disorders	5,793	11%	<ul style="list-style-type: none"> • Rivotril - Acquired from Roche; innovator/textbook brand of clonazepam with strong recall among neurologists & psychiatrists. • Expand into the fast-growing epilepsy & anxiety segment, leveraging Mankind's pan-India specialist reach

Foray into Onco and Transplant business through acquisition of Panacea

1. Molecule Market Size for Neptaz, all others are at Group level || # In-licensed || *Acquired



Consumer Healthcare Segment Revenue (INR Cr)



- ❖ Revenue growth of 20% YoY in Q4FY26 primarily driven by strong growth in Manforce, Prega News, Gasofast and Nimulid
- ❖ MT & E-Com share increased to 13% in FY26 as compared to 9% in FY25 supported by 57% growth
- ❖ Healthy growth in secondary sales² for Gas-o-fast, Prega News and Ova news of 24%, 28% and 65% YoY respectively in Q4FY26

1. Denotes EBITDA adjusted with one time labour code impact, reported EBITDA is 21.0% in Q4 and 18.3% in FY26 || 2. As per IQVIA / IQVIA Retail Mar 2026

Strong Corporate Identity Complements Brand Recall...

Strategically selected national and regional brand ambassadors

Corporate Brand Ambassadors



Dominant Brands



#1
Condom Brand
Market Share - 28%



#1
Pregnancy Test Kit Brand
Market Share - 83%



#2
Antacid Powder Brand
Market Share - 11%



#8
Vitamins, Minerals,
Nutrients Brand
Market Share - 2.4%



#1
Medicated Anti-Acne
Brand
Market Share - 33%



#5
Pain Management Brand
Market Share - 1.3%



#1
Emergency Contraceptive
Brand
Market Share - 68%

Consumer Healthcare Brand Ambassadors




Sunny Leone




Manasvi Mamgai



Anushka Sharma



Kajal Aggarwal



Srabanti Chatterjee



Paresh Rawal




Brahmanandam



Biswanath Basu



Ranveer Singh



Rashi Khanna



Rajkumar Rao

...With Targeted Marketing Initiatives

MANforce
Condoms



Launching the Valentine's Day Video Campaign for Epic Aura Massager



King Dot & King Thin Digital Video Promotion



Valentine's Day Digital Video Campaign for EPIC THINX across platforms

Prega News
Means Good News



Women's Day Campaign #SheCanCarryBoth Highlighting Postpartum Depression



GAS-O-FAST
SACHETS



On-ground brand activations in UP, Punjab, Rajasthan and Khatu Shyamji area



Mankind's **HealthOK**
MULTIVITAMIN TABLETS



Strategic collaboration with Haldiram to strengthen penetration in the vegetarian consumer segment



Nationwide Cinema Campaign featuring HealthOK DVC during Dhurandhar Part 2 Screenings

NIMULID
STRONG




Sampling in Marathons & Sports events



Bus Branding Campaign across Madhya Pradesh & Chhattisgarh

Exports Business Update


Revenue from Exports (INR Cr)¹



- ❖ Revenue from International business witnessed muted growth of 4% YoY in Q4FY26 impacted due to geo-political headwinds
- ❖ Mankind (excluding BSV) has launched 4 new products in FY26 taking the total launched products to 48 in US

1. Denotes reported number including BSV from 23-Oct-2024

ESG : Organization Focus on Sustainable Growth FY26




British Safety Council Award Unit-II

- 10% increase in total Renewable energy usage in FY26 than FY25.
- 61.4% waste water recycled in FY26 i.e 4.4% increased compared to FY25.
- 46% of significant suppliers have been assessed on ESG and endorsed the company's Third Party code of conduct.
- Rated "Aspiring" Category by National Stock Exchange, SEBI.
- International Safety Award from British Safety Council – Unit-I, II, BSV and API-1.
- Best Occupational Health and safety from Golden Peacock Award for Unit 1.
- National Safety Council of India Award to Unit-III.













- Voluntary ESG report FY25 beyond BRSR, aligned with Global frameworks (GRI, UNSDG).
- Standardized Sustainable Procurement Governance through formalized Third Party code of conduct aligned with Procurement Policy.
- Training and Capacity building for top upstream value chain partners contributing 2% of total procurement.
- AMR (Anti Microbial resistance) testing carried out for Units Handling antibiotic products-in compliance.
- Two layer Sustainability governance Council under Board level committee.

- Double Materiality Assessment and TCFD Study to determine risk and opportunities and financial implications.
- Third Party assured Sustainability Report aligned with Global Reporting frameworks like GRI.
- Evaluate Scope 3 emissions for all applicable categories.
- British Safety Council 5 Star Audit at Unit-3.
- ISO 50001, Energy Management system implementation for Unit-2.
- ISO 14001 & 45001 Certification – Udaipur.
- Auto foam flooding system implementation in API-1.

- Digitalization of Contractor safety management.
- Unit-1: Commissioning of New ETP expansion and waste water recycling plant.
- Commissioned dedicated ETP and installed ductless fume hood at R&D BSV.
- Full Automation of Hydrogenation plant at API-2.



ESG Goals & Status FY26

Area	GOAL ¹	Status FY26
 <p>Occupational Health and Safety</p>	<p>ZERO Lost Time Accidents</p>	 <p>No Lost Time Accident across all manufacturing & New Project sites</p>
 <p>Carbon Neutral (Scope 1 & Scope 2 emissions)</p>	<p>100% by FY'30</p>	<p>72%² reduction in FY26 from base year FY21</p> 
 <p>Hazardous Waste Disposal for co-processing</p>	<p>70% by FY'27</p>	<p>69% disposal for co-processing (energy recovery)</p> 
 <p>Renewable Power Usage</p>	<p>100% RP by FY'30</p>	<p>92% electricity from renewable sources</p> 
 <p>Reduce Ground water Intensity/Million Tablets</p>	<p>50% by FY'30</p>	<p>37% reduction in ground water intensity Per Mn Tablets from base year FY20</p> 
 <p>Wild Life Conservation Plan</p>	<p>Implementation by FY'35</p>	 <p>Approval awaited from wildlife board</p>

1. Considering boundary of Unit I, II, III, Sikkim || 2. 5% increase in absolute emissions due to 6% production increase



Additional Information

Mankind Pharma at a Glance (FY26)



#1

Rank in Prescriptions over the last nine years¹

#2

Rank by volume in IPM¹

#4 / #1

Rank by value in IPM¹ / Gynaecology

4

Consumer Healthcare brands ranked #1 in their categories¹



INR 14,278 Cr

FY26 Revenue

86%

FY26 Domestic Revenue

54/22

Brand families¹ worth INR 50/100 Cr+

18,500+

Mar'26 Field force²



18.1%

Revenue CAGR FY21-26

15.2%

Domestic Business Revenue CAGR FY21-26

13.6%

Consumer Healthcare Revenue CAGR FY21-26

16.9%

Adj. EBITDA CAGR FY 21-26



25.4%

FY26 Adj. EBITDA Margin³

13.6%

FY26 PAT Margin


12% / 41%

FY26 ROCE⁴ Inc. BSV / Exc. BSV

1.1x

FY26 Net Debt / Adj. EBITDA³

Key Milestones - Disruption led growth



4th Largest Pharma Company in India with a market share¹ of 4.7% in MAT Mar'26

Consistently Expanding to Specialty and Super Specialty

Mass Market
(Acute/ Chronic / Semi Chronic)



Specialty Chronic
(Cardio / Diabeto / CNS)



Consumer Healthcare (OTC)



BSV - Super Specialty

Targeted Medical Practitioners



Targeted Medical Practitioners



Targeted Medical Practitioners



₹ INR 11,338 Cr
Domestic Revenue¹
(FY26)

28%/ 39%
Increase Chronic Share³
(FY18 / FY26)

₹ ~INR 879 Cr
Revenue (FY26)

High entry barrier portfolio with
specialty R&D tech platform

15.2%
Revenue Growth²
(FY21-26)

12+ divisions launched to
focus on Specialty
Chronic

4 Brands
Ranked³ #1 in
Consumer Health

Ranked #1/#2 in 9 key brand³
families with limited
competition in India

#4 / #2
Rank³ in IPM value /
Volume (FY26)

Acquired the specialty
Onco and Transplant
brands from Panacea

~28%
MS³ in Condoms

**Recombinants, Niche
Biologics, Novel Delivery
and Immunoglobulins**

~16,800 Field Force
22 Brands³ >100 Cr in
FY26

4
In-licensed / acquired
super specialty Chronic
products from MNCs -
**2 from Novartis, 1
each from Astra
Zeneca, and Roche**

83%/68%
MS³ in Pregnancy Test
Kits/ Emergency
Contraceptive

**Brands across the Women's Health
Lifecycle in India; Comprehensive
Fertility drug portfolio globally**

Mankind has consistently evolved having a comprehensive portfolio across the pharma value chain

Key Strengths

India revenues contribute **86%** of total revenues in FY26

Consistent CFO/ EBITDA ratio of ~80% during FY26

Best in class cash conversion metrics

Focus on domestic business

Volume-growth driven by affordability

#2 rank by volume in IPM¹

75% of manufacturing in-house; track record of innovation with commercialization of “**Dydrogesterone**”

Strong In-house manufacturing & proven R&D capabilities



Mankind
Serving Life

Growing franchise of scaled brands

22 / 13 brand families worth over INR 100 / 200 crore¹

Largest doctor coverage of 5 lac doctors, backed by a **18,500+** field force

#1 in prescriptions in India over last 9 years

7

4

Increasing share of Chronic Segment

Chronic share^{1,2} increased from 28% in FY18 to ~**39%** in FY26

One of the largest distribution networks with **12,000+** stockiest across the country

Pan-India Market and Distribution Coverage

6

5

Fast growing consumer healthcare franchise

4 brands ranked #1 in consumer healthcare segment¹

Strategy Going Ahead



Consolidate market share in increased CVM - Deeper penetration in incremental CVM¹ (62% in FY21 to 72% in FY26) driven by volume focused growth and **scaling up brands**.



Increasing chronic share - Increasing presence in chronic therapies (**Diabetes - Empagliflozin**, and Insulin Glargine, **Respiratory - Inhalers**) and expansion into new therapies like **CNS, Urology**



Expanding towards super specialty portfolio - M&As (**Acquired BSV** to add high entry barrier complex portfolio; Leadership in Women's Health). **In-licensing / brand acquisitions from MNCs** (Novartis, Astra Zeneca and Roche).



Increase penetration in Metros/Tier I cities - **Engaging KOLs, hospital tie-ups, specialty division launches** and inorganic growth initiatives, **launching DMF grade products** (240+ SKUs launched) and build alternative channels of growth including modern trade.



Grow consumer healthcare business - Leveraging existing brand equity, additional distribution models, **Rx to OTx to OTC**



Higher Focus on R&D - To build on **BSV R&D tech platform along with Mankind** to expand in high entry barrier complex products




Continue developing digital platforms to enhance productivity - **Strengthening medical content for evidence based marketing**; end-to-end business transformation through AI/ML based technologies to improve productivity and efficiency




Build an institution — strengthening foundation by **formulating best in class people, policies and processes** for long term sustainable growth.

Financials¹ - Steady Growth Trajectory


Revenue (INR Cr)




Strong Growth in Domestic Revenue (INR Cr)



Revenue from Exports (INR Cr)



EBITDA (INR Cr) and Margin %⁽²⁾




1. FY24 and FY25 P&L items are for continuing operations only and hence prior period numbers are strictly not comparable || 2. EBITDA refers to profit for the year/period, as adjusted to exclude (i) other income, (ii) depreciation and amortization expenses, (iii) finance costs and (iv) total tax expense. EBITDA Margin refers to the percentage margin derived by dividing EBITDA by revenue from operations || 3. Adjusted with one-time M&A related expenses and other non-recurring cost || 4. Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results)

Key Performance Highlights

Key Performance Highlights	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Value Growth YoY in IPM (%)	11.3	12.6	12.5	11.1	17.7	10.6	8.5	7.5	8.2
Market share by Value in IPM (%)	3.9	4.0	4.1	4.3	4.3	4.4	4.4	4.8	4.7
Market Ranking by Value in IPM (x)	4	4	4	4	4	4	4	4	4
CVM share in total IPM (%)	60.2	61.6	62.4	62.2	65.4	68.1	68.8	72.3	72.3
Market Share in covered market (%)	6.6	6.5	6.5	6.9	6.6	6.5	6.4	6.7	6.6
Covered market Rank by Volume (x)	2	2	2	2	2	2	2	2	2
Volume Share in IPM (%)	4.8	5.1	5.2	5.7	5.5	5.7	5.8	6.0	6.1
Market Ranking by Volume in IPM (x)	5	3	3	3	3	3	3	2	2
Chronic Share in Total portfolio (%)	27.9	31.9	32.2	34.1	32.9	33.9	35.5	37.1*	38.5*
Chronic Growth YoY (%)	16.4	28.6	13.5	17.6	13.6	14.1	13.5	11.9*	13.2*
Metro & Class 1 Share (%)	49.9	49.2	48.1	51.8	52.9	53.2	53.0	55.5	57.0

Shareholding Pattern



■ Promoters ■ FPI & Bodies Corporate ■ Mutual Funds ■ Retail ■ Others

BSE Ticker	543904
NSE Symbol	MANKIND
# of Shares outstanding*	41,28,28,328
Share Price*	2,005.80
Market Cap. (INR Cr)*	82,805
% Free Float	27.5%
Free Float Market Cap. (INR Cr)	22,771
Industry	Pharmaceuticals

- **ROCE** = (EBIT for the year) / (Capital employed less cash)
 - EBIT excludes other income
 - Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash.
- **Adjusted ROCE** = (Adjusted EBIT for the year)/ (Adjusted Capital employed less cash)
 - Adjusted EBIT excludes M&A related and other non-recurring impact and other income
 - Adj. Capital employed is the (excluding acquisition) sum of total equity, total borrowings, total lease liabilities, deferred tax liabilities (net), M&A related impact (net of Tax) less deferred tax assets, Cash and cash used for acquisitions.
- **Cash** = (Cash and cash equivalents + Other bank balances + investment in Mutual funds + Bank Deposits (Other Financial Assets))
- **Net Cash** = (Cash - Current borrowings - Non Current borrowings at the end of the period)
- **Net Operating Working Capital Days** = (Average operating working capital / Revenue from operations) X 365 days.
Operating working capital is the sum of Inventories and Trade receivables less Trade payables less payable to employees (other financial liabilities)
- **Cash EPS** = Profit/(Loss) for the period plus Depreciation, Amortization and Impairment / weighted average number of equity shares outstanding during the period



Q4 & FY26 Earnings Call Details



Date	20 th May, 2026
Time	12:00 PM - 01:00 PM IST
Link	
Zoom Call	https://us06web.zoom.us/webinar/register/WN_gjCF6TrYR9eK24zP-RYSZQ

The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goal”, “likely”, “project”, “should”, “potential” “will”, “may”, “targeting” or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward-looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance.

The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, the Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise.

Thank You

For more information please visit our website:

<https://www.mankindpharma.com>

For specific queries, contact:

Abhishek Agarwal

Head - Investor Relations & Strategy

011 - 46846700 Ext. 3532

Investor.relations@mankindpharma.com

